Acute myocardial infarction (AMI) remains one of the leading causes of mortality and morbidity worldwide. Early diagnosis and accurate prognosis are vital to improve patient outcomes. Heart-type Fatty Acid-binding Protein (H-FABP) has emerged as a potential biomarker for AMI. H-FABP is a cytoplasmic protein encoded by the FABP3 gene, situated on chromosome 1 in the human genome. It plays a crucial role in active fatty acid metabolism and is implicated in the absorption, cellular metabolism, and/or transport of polyunsaturated fatty acids (PUFAs). During the pathogenesis of acute coronary syndrome (ACS), H-FABP is rapidly released into the circulation when myocardial ischemic injury occurs. Its early detection, around 1-2 hours after AMI, with a peak at 5-10 hours, and normalization within 24-36 hours, makes H-FABP an ideal candidate for early diagnostic and prognostic evaluation in AMI patients. Despite its excellent prognostic value, H-FABP's diagnostic sensitivity outweighs its specificity for AMI. This review discusses the potential of H-FABP as an early diagnostic and prognostic marker for AMI and emphasizes further studies and research are needed regarding the use of H-FABP as a diagnostic and/or prognostic marker for AMI.
Copyrights © 2023